Patents Assigned to INSTITUT PAOLI-CALMETTES
-
Publication number: 20190323085Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.Type: ApplicationFiled: February 28, 2019Publication date: October 24, 2019Applicants: Qiagen Marseille SA, Institut Paoli-Calmettes, INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: Véronique Gelsi-Boyer, Daniel Birnbaum
-
Patent number: 10385137Abstract: The invention concerns antibody formats comprising VH sequence of Camelidae, such as llamas; antibodies of various formats have anti-CEA or anti-CD16 VH sequences thereof; vectors expressing the antibody formats, and methods for producing the same.Type: GrantFiled: September 16, 2015Date of Patent: August 20, 2019Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre National de la Recherche Scientifique (CNRS), Universite d'Aix Marseille, Universite de Montpellier, Institut Regional du Cancer de Montpellier-Val D'Aurelle, Institut Paoli CalmettesInventors: Daniel Baty, Ghislaine Behar, Martine Mansais, Andre Pelegrin, Jean-luc Teillaud, Isabelle Teulon
-
Publication number: 20150353643Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.Type: ApplicationFiled: July 6, 2015Publication date: December 10, 2015Applicants: UNIVERSITE DE LA MEDITERRANEE - Aix-Marseille II, INSTITUT PAOLI-CALMETTES, Institut National de la Santé et de la Recherche Médicale (INSERM)Inventors: Daniel OLIVE, Marc BONNEVILLE, Emmanuel SCOTET, Christelle HARLY, Yves GUILLAUME
-
Patent number: 9193699Abstract: Provided are compounds of formula (I): wherein R1, R2, R3, R4 and R5 are independently selected from the group comprising, inter aliae, H, optionally substituted, branched or linear C1-C12 alkyl, halogen atom and C1-C12 haloalkyl, and wherein A represents a single bond or an optionally substituted C1-C6 alkylene radical, notably useful for the treatment of human cancers.Type: GrantFiled: October 4, 2012Date of Patent: November 24, 2015Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), UNIVERSITÉ D'AIX-MARSEILLE, L'INSTITUT PAOLI-CALMETTESInventors: Marc Lopez, Yves Collette, Lynda Mezil, Jean-Michel Brunel, Sebastien Combes
-
Patent number: 9169316Abstract: The invention concerns an in-vitro method for introducing a targeted genome modification into an oocyte or an egg and a method for performing a random insertion in the genome of a host cell.Type: GrantFiled: June 13, 2007Date of Patent: October 27, 2015Assignees: Centre National de la Recherche Scientifique-CNRS, INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix Marseille, Universite de Montpellier, Institut Regional du Cancer de Montpellier-Val d'Aurelle, Institut Paoli CalmettesInventors: Daniel Baty, Ghislaine Behar, Martine Chartier, André Pelegrin, Jean-luc Teillaud, Isabelle Teulon
-
Publication number: 20150125868Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.Type: ApplicationFiled: October 10, 2014Publication date: May 7, 2015Applicants: Qiagen Marseille SA, Institut Paoli-Calmettes, INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: VÉRONIQUE GELSI-BOYER, DANIEL BIRNBAUM
-
Publication number: 20140322235Abstract: The present invention relates to anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vy9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The invention also relates to the use of said antibodies in therapy.Type: ApplicationFiled: December 14, 2011Publication date: October 30, 2014Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), INSTITUT PAOLI-CALMETTES, UNIVERSITE DE LA MEDITERRANEE - Aix-Marseille IIInventors: Daniel Olive, Marc Bonneville, Emmanuel Scotet, Christelle Harly, Yves Guillaume
-
Publication number: 20130079234Abstract: A method for predicting the sensitivity of tumor cells to an anthracycline-based chemotherapy includes determining the differential expression level of a MYBL2 gene in tumors cells. A polynucleotide library is useful to predict the sensitivity of tumor cells to an anthracycline-based chemotherapy and includes a pool of polynucleotide sequences or subsequences thereof wherein the sequences or subsequences correspond substantially to any of the polynucleotide sequences SEQ ID No: 308, SEQ ID No: 309 and/or SEQ ID No: 310 or the complements thereof.Type: ApplicationFiled: May 26, 2011Publication date: March 28, 2013Applicants: Institut Paoli-Calmettes, IPSOGEN, SASInventors: Francois Bertucci, Rémi Houlgatte, Daniel Birnbaum, Catherine Nguyen, Patrice Viens, Vincent Fert
-
Publication number: 20130059301Abstract: A method for diagnosing a myeloid cancer in a subject, includes the step of analyzing a biological sample from the subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID N°2. A kit for diagnosing myeloid cancer in a subject including at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method is also described.Type: ApplicationFiled: February 11, 2011Publication date: March 7, 2013Applicants: INSTITUT PAOLI-CALMETTES, IPSOGENInventors: Véronique Gelsi-Boyer, Daniel Birnbaum
-
Publication number: 20110244459Abstract: Methods for identifying ERBB2 (also named HER2) alteration in tumors, in particular cancer, based on the analysis of the expression of at least three genes of the ERBB2 amplicon located within less than one megabase on either side of ERBB2, and eventually of the gene corresponding to the Affymetrix probeset 234046_at (SEQ ID NO: 31), as well as a poynucleotide library useful for the molecular characterization of a cancer including polynucleotide sequences for detecting the genes, and a kit including the library.Type: ApplicationFiled: December 9, 2009Publication date: October 6, 2011Applicants: IPSOGEN, INSERM-INSTITUT NATIONAL DE LA SANTE ET DE LA rECHERCHE MEDICALE, INSTITUT PAOLI-CALMETTESInventors: Francois Bertucci, Rebecca Tagett, Sabrina Carpentier
-
Publication number: 20110086765Abstract: Method for molecular characterization of a carcinoma including: (i) detecting in tumor cells corresponding to breast tumor cells at least one polynucleotide selected from a first group determining expression level of the polynucleotide from the first group to differentiate a tumor in which a lymph node has been invaded by a tumor cell from a tumor in which a lymph node has not been invaded by a tumor cell; (ii) detecting in tumor cells corresponding to breast tumor cells at least one polynucleotide selected from a second group determining expression level of the polynucleotide from the second group to distinguish tumors sensitive to anthracycline from tumors insensitive to anthracycline; (iii) detecting in tumor cells corresponding to breast tumor cells at least one polynucleotide selected from a third group determining expression levels of the polynucleotide from the third group to classify good and poor prognosis primary breast tumors.Type: ApplicationFiled: October 13, 2010Publication date: April 14, 2011Applicants: IPSOGEN, SAS, Institut Paoli-CalmettesInventors: Francois Bertucci, Rémi Houlgatte, Daniel Birnbaum, Catherine Nguyen, Patrice Viens, Vincent Fert
-
Publication number: 20110014191Abstract: The present invention relates to a method for analyzing cancer. e.g., breast cancer including detection of differential expression of at least one of the 16 genes encoding serine/threonine kinases listed in Table 1, or of the 16 genes, and to a polynucleotide library including at least one the 16 genes. This finds use in the development of novel applications, in particular in the development of prognosis or diagnostic of breast cancer or for monitoring the treatment of a patient with a breast cancer.Type: ApplicationFiled: December 24, 2008Publication date: January 20, 2011Applicants: IPSOGEN, INSTITUT PAOLI-CALMETTESInventors: Francois Bertucci, Daniel Birnbaum, Pascal Finetti
-
Publication number: 20100234292Abstract: The present invention relates to a method of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer in view of the expression of specific nucleic acid sequences in a biological sample.Type: ApplicationFiled: April 16, 2008Publication date: September 16, 2010Applicants: IPSOGEN, INSERM - INSTITUT NATIONAL DE LA SANTE ET DE LA RE CHECHE MEDICALE, INSTITUT PAOLI-CALMETTESInventors: Francois Bertucci, Daniel Birnbaum, Patrice Viens, Vincent Fert, Fabienne Hermitte, Stephane Debono, Stephane Deraco, Nathalie Borie, Fanny Piette
-
Publication number: 20050221398Abstract: A method for analyzing differential protein expression associated with histopathologic features of breast disease including detecting overexpression or underexpression of a pool of proteins in breast tissues or cells, the pool including at lease one of a protein set including Afadin, Aurora A, a-Catenin, b-Catenin, BCL2, Cyclin D1, Cyclin E, Cytokeratin 5/6, Cytokeratin 8/18, E-Cadherin, EGFR, ERBB2, ERBB3, ERBB4, Estrogen receptor, FGFR1, FHIT, GATA3, Ki67, Mucin 1, P53, P-Cadherin, Progesterone receptor, TACC1, TACC2, TACC3, Cytokeratin 6, Cytokeratin 18, Ang1, AuroraB, BCRP1, CathepsinD, CD10, CD44, CK14, Cox2, FGF2, GATA4, Hif1a, MMP9, MTA1, NM23, NRG1a, NRG1beta, P27, Parkin, PLAU, S100, SCRIBBLE, Smooth Muscle Actin, THBS1 and TIMP1.Type: ApplicationFiled: January 18, 2005Publication date: October 6, 2005Applicants: Ipsogen, SAS, a corporation of France, INSERM, a corporation of France, Institut Paoli-Calmettes, a corporation of FranceInventors: Jocelyne Jacquemier, Francois Bertucci, Daniel Birnbaum, Stephane Debono, Rebecca Tagett